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In the 21st century, chikungunya virus (CHIKV) has emerged as a mosquitoborne disease of glob-
al relevance, causing large epidemics because of its 
widespread dissemination in tropical and subtropical 
areas (1). Infected persons usually develop an acute 
febrile illness associated with joint pains, myalgia, 
headache, and other signs and symptoms that can 
lead to misdiagnosis with other arboviral illnesses, 
such as dengue virus (DENV) and Zika virus (ZIKV) 
infections. Noteworthy with chikungunya, the ar-
thralgia is often severely debilitating and may last for 
months to years (1,2). 
After the introduction of CHIKV into the Carib-
bean region in 2013, the virus spread rapidly, caus-
ing large outbreaks (3,4). In certain Caribbean islands, 
such as Puerto Rico and the US Virgin Islands, the 
rate at which CHIKV infection was symptomatic was 
estimated at >70% (5,6). However, it remains unclear 
whether the attack rates in outbreaks in large popu-
lation centers in the Americas created sufficiently 
high levels of herd immunity to preclude subsequent 
epidemics. Furthermore, 2 CHIKV strains were in-
troduced and are cocirculating in the Americas; it is 
unclear whether the proportions of symptomatic in-
fections differ on the basis of strain type, population, 
or region. 
In Brazil, CHIKV was first detected in September 
2014, almost simultaneously in the cities of Oiapoque, 
in the northern state of Amapá, where the Asian gen-
otype was implicated (7), and in Feira de Santana, in 
the northeast state of Bahia, where the East/Central/
South African (ECSA) genotype was detected (7,8). The 
virus spread rapidly throughout the country, reach-
ing all states by 2015 (9), and peaked in 2016, when 
≈280,000 probable cases were recorded (10). The north-
east region was the most affected by CHIKV (9,10,11); 
this same area was also the most affected by ZIKV in 
2015–2016 (12,13). 
In Salvador (population 2.9 million [14]), the capi-
tal of Bahia state, which is located ≈100 km from Feira 
de Santana, we retrospectively identified that CHIKV 
had been circulating since September 2014 (15), but 
outbreaks first occurred between June and November 
2015 (12,15). In this study, we used the prevalence 
of CHIKV IgG as an indicator of all (i.e., symptom-
atic and asymptomatic) previous infection in a slum 
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After a chikungunya outbreak in Salvador, Brazil, we 
performed a cross-sectional, community-based study of 
1,776 inhabitants to determine chikungunya virus (CHIKV) 
seroprevalence, identify factors associated with expo-
sure, and estimate the symptomatic infection rate. From 
November 2016 through February 2017, we collected so-
ciodemographic and clinical data by interview and tested 
serum samples for CHIKV IgG. CHIKV seroprevalence 
was 11.8% (95% CI 9.8%–13.7%), and 15.3% of seropos-
itive persons reported an episode of fever and arthralgia. 
Infections were independently and positively associated 
with residences served by unpaved streets, a presump-
tive clinical diagnosis of chikungunya, and recall of an epi-
sode of fever with arthralgia in 2015–2016. Our findings 
indicate that the chikungunya outbreak in Salvador may 
not have conferred sufficient herd immunity to preclude 
epidemics in the near future. The unusually low frequency 
of symptomatic disease points to a need for further longi-
tudinal studies to better investigate these findings. 
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community of Salvador and assessed the proportion 
of cases in which these infections were symptomatic. 
In addition, we investigated factors potentially asso-
ciated with prior CHIKV infection. 
Methods 
Study Site and Participant Selection
We performed a cross-sectional study in Pau da 
Lima, a poor community in Salvador characterized 
by high population density and substandard sani-
tation infrastructure (16,17). Since 2003, this com-
munity has been the site for several studies aiming 
to determine the epidemiology and the transmis-
sion dynamics of leptospirosis (17–19), dengue, and 
other arboviral diseases (15,16,20,21), as well as the 
burden of chronic noncommunicable diseases on 
the community and its residents (22,23). Detailed 
information about the sociodemographics of the 
Pau da Lima community, environment, and urban 
infrastructure has been previously described in 
these studies.
We surveyed the residents of 3 contiguous val-
leys in Pau da Lima from November 2016 through 
February 2017. During the enrollment process, we 
visited all households in the study site and invited 
all residents ≥5 years of age who slept ≥3 nights per 
week in the house to participate. 
Data Collection
We used a standardized questionnaire during house-
hold visits to obtain data on participant demographic 
and socioeconomic conditions. Data collected were 
age, sex, self-reported skin color, education level, oc-
cupation or work, household per capita income, ma-
terial of housing walls (wood or other material that is 
not brickwork, plastered or not plastered), quality of 
streets accessing house (paved or unpaved), and num-
ber of residents per household (Appendix, https://
wwwnc.cdc.gov/EID/article/26/7/19-0846-App1.
pdf). We also collected self-reported data on prior 
presumptive clinical diagnosis of DENV, ZIKV, and 
CHIKV infection and on history of fever, arthralgia, 
myalgia, rash, and pruritus, at any time after January 
2015. This information covered health effects from 
the period immediately before and after the peak of 
CHIKV transmission in Salvador, which occurred 
during June–November 2015 (12,15). We recorded 
the duration of arthralgia among participants who 
reported this symptom. We conducted the interviews 
on computer tablets and used Research Electronic 
Data Capture software (REDCap; https://projectred-
cap.org/software/) to store the data (24). 
Serologic Evaluation
During the household visits, we collected 10 mL of 
blood from each participant and transported the 
samples on the same day, stored at 2°C–8°C, to our 
laboratory at the Instituto Gonçalo Moniz, Fundação 
Oswaldo Cruz, in Salvador. We centrifuged the sam-
ples to obtain serum, which we aliquoted and stored 
at -20°C until evaluation. We tested serum samples by 
using the IgG ELISA technique (Euroimmun, https://
www.euroimmun.com) to detect specific CHIKV IgG. 
For samples showing positive results for IgG, 
we then tested with a CHIKV IgM ELISA (InBios, 
https://inbios.com); we used the presence of IgM as a 
proxy for a more recent CHIKV infection than if there 
were no IgM. We interpreted both the CHIKV IgG 
and IgM ELISA results according to manufacturer in-
structions: CHIKV IgG absorbance/calibrator levels 
were negative at <0.8, indeterminate at ≥0.8 to <1.1, 
and positive at ≥1.1; CHIKV IgM absorbance/calibra-
tor levels were negative at <0.9, indeterminate at ≥0.9 
to <1.1, and positive at ≥1.1. We retested samples in-
dicating indeterminant results on the initial test and 
considered the results obtained final. 
To confirm the accuracy of results from the IgG 
ELISA, we performed a blind plaque-reduction neu-
tralization test (PRNT) of a stratified random sample 
of 60 serum samples (30 positive and 30 negative from 
the CHIKV IgG ELISA) for CHIKV to determine ≥90% 
reductions in plaque counts (PRNT90), as described 
elsewhere (25). To investigate whether cryoglobuli-
nemia could have reduced the sensitivity of the IgG 
ELISA, we retested 100 samples, randomly selected 
from those that had been IgG negative, using a pre-
warmed (2 h at 37°C) and centrifuge protocol (26). 
Data Analysis
We used absolute and relative frequencies or medi-
ans and interquartile ranges (IQR) to characterize the 
sociodemographics and also reported presumptive 
diagnoses and history of symptoms of study partici-
pants. We used χ2 or Wilcoxon rank-sum tests to com-
pare the sex and age distribution for those who did 
agree to be enrolled in the study with the distribution 
for those who did not. We used a 2-tailed p value of 
<0.05 to define statistically significant differences. 
We calculated the prevalence of CHIKV IgG 
overall and according to participants’ characteristics 
and categorized continuous variables so we could 
estimate CHIKV seroprevalence by groups. We 
stratified age into ranges of 5–14 years, 15–39 years, 
and ≥40 years to account for the disproportionately 
young average age of the sample; we characterized 
education level as illiterate for participants who had 
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never studied and literate for participants who had 
studied >1 year. We determined those living in pov-
erty using the World Bank’s criteria for poverty in 
upper-middle-income countries of <$5.50/day (US 
dollars) per capita household income (27). We ob-
tained 95% CIs for the prevalence measures, adjust-
ing them for the design effect of sampling house-
holds as clusters. 
We used bivariate and multivariate Poisson re-
gression models with robust variance and adjustment 
for design effect to verify associations between previ-
ous CHIKV infection and the sociodemographic and 
clinical characteristics of participants. We calculated 
prevalence ratios with 95% CIs and included all vari-
ables that had bivariate analyses with a p value <0.20 
in the multivariate analyses. We then used a back-
ward selection method to build 2 final multivariate 
models, retaining variables with a p value <0.05. The 
first model included only sociodemographic variables 
to investigate their role in CHIKV infection, whereas 
the second model included only clinical characteris-
tics to address their capacity to predict a positive se-
rologic result. 
Among the participants with a positive CHIKV 
IgG ELISA, we estimated the frequencies of symp-
tomatic CHIKV infection by calculating the propor-
tion of those who reported fever simultaneously ac-
companied by arthralgia after January 2015, likely 
recent CHIKV infection by calculating the proportion 
of those with a positive IgM test result, and presump-
tive clinical suspicion of chikungunya by calculating 
the proportion of those who reported having received 
that diagnosis. Wilcoxon rank-sum test was used to 
compare the median duration of arthralgia between 
those reporting arthralgia accompanied by fever and 
those reporting only arthralgia. Poisson regression 
models with robust variance, adjusted for design ef-
fect, were used to compare sociodemographic and 
clinical characteristics between participants with 
symptomatic CHIKV infections and those with as-
ymptomatic infections and between participants with 
likely recent and those with likely nonrecent CHIKV 
infections. We set a two-tailed p value <0.05 to define 
statistically significant differences. We performed 
data analysis using Stata version 14 software (Stata-
Corp, https://www.stata.com) (28). 
Ethics Considerations
This study was approved by the Research Ethics Com-
mittee of Gonçalo Moniz Institute, Oswaldo Cruz 
Foundation (CAAE n° 55904616.4.0000.0040). Before 
any study procedure, all participants ≥18 years of age 
signed an informed consent form; those <18 years of 
age who were able to read signed an informed assent, 
with their parents providing a signed consent. 
Results 
Participants Characteristics
Among the 2,651 eligible residents in the study site, 
1,776 (67.0%) agreed to participate in this study. Those 
who consented were younger than those who refused 
(median age 26 years [IQR 16–40] vs. 35 years [IQR 
21–46]; p <0.01). Of those who consented, a greater 
proportion were female (57.0%) than those who did 
not consent (52.0%; p<0.01). Most participants had a 
nonwhite (black or mixed) skin color (93.8%), lived in 
a household with a per capita income <$5.50/day (US 
dollars) (80.8%), and had not completed elementary 
school education (59.0%) or were illiterate (4.3%). 
Prevalence of Previous CHIKV Infection and  
Associated Factors
Among the 1,772 (99.8%) participants from whom we 
collected and tested a blood sample, 209 (11.8%, 95% 
CI 9.8%–13.7%) had had a previous CHIKV infec-
tion, as determined by the detection of CHIKV IgG. 
Of the 30 random IgG ELISA positive samples tested 
by CHIKV PRNT90, 27 (90%) were positive; of the 30 
random IgG-negative samples, all were also negative 
in PRNT90 (agreement 95%; kappa 90%). Of the 100 
IgG-negative samples that we retested to evaluate 
whether cryoglobulinemia had reduced ELISA sensi-
tivity, 2 (2%) returned positive results, but these re-
sults had low absorbance/calibrator levels (1.11 and 
1.15) compared with those observed for the 209 posi-
tive samples (median 3.53, IQR 3.11–3.82). 
In bivariate analyses, prevalence of previous 
CHIKV infection did not differ by sex, skin color, pov-
erty level, or number of residents per household (Ta-
ble 1). However, we found a statistically significant 
association with other indicators of socioeconomic 
status, residing on unpaved streets and living in 
houses whose walls were unplastered or were made 
of wood or other materials; in addition, we found a 
nonsignificant trend of greater prevalence among 
participants who were older, illiterate, or reported 
not working (Table 1). Furthermore, the prevalence of 
previous CHIKV infection was statistically greater for 
participants who had received a presumptive clinical 
diagnosis of an infection by any of 3 cocirculating ar-
boviruses—CHIKV, DENV, or ZIKV—and for those 
who reported having symptoms compatible with an 
arboviral infection—fever with arthralgia, myalgia, 
rash, or pruritus—after January 2015, when CHIKV 
emerged in Salvador (Table 1).
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The only sociodemographic characteristic associ-
ated with previous CHIKV infection in the multiple 
variable analyses was residence on an unpaved street 
(prevalence ratio [PR] 1.52, 95% CI 1.07–2.15) (Table 
2). In addition, independent clinical predictors for 
previous CHIKV infection included recall of a pre-
sumptive medical diagnosis of chikungunya (PR 2.83, 
95% CI 1.97–4.05) and report of an episode of fever 
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Table 1. Prevalence of previous chikungunya virus infection, determined by detection of IgG, by demographic and clinical 
characteristics, Salvador, Brazil, November 2016–February 2017 
Characteristic No. participants No. positive (prevalence, %) p value 
Sociodemographic    
 Sex    
  M 761 93 (12.2) 0.60 
  F 1,011 116 (11.5)  
 Age, y    
  5–14 396 41 (8.1) 0.35 
  15–39 921 104 (11.9)  
  ≥40 455 63 (14.9)  
 Skin color    
  Nonwhite 1,662 199 (12.0) 0.39 
  White 110 10 (9.1)  
 Household per capita income in US$/day*    
  ≤5.50 1,429 171 (12.0) 0.69 
  >5.50 340 37 (10.9)  
 Education    
  Illiterate 76 14 (18.4) 0.06 
  Literate 1,696 195 (11.5)  
 Occupation/work    
  Yes 604 60 (9.9) 0.08 
  No 1,164 148 (12.7)  
 Residence located in an unpaved street    
  Yes 1,003 139 (13.9) 0.02 
  No 767 70 (9.1)  
 Type of residence construction    
  Plastered wall 1,447 154 (10.6) 0.04 
  Unplastered wall 211 33 (15.6)  
  Wood or other material 106 21 (19.8)  
 Residents per household    
  1 145 13 (9.0) 0.31 
  2–3 676 89 (13.2)  
  4–5 608 60 (9.0)  
  ≥6 340 5 (13.5)  
Clinical: reported symptoms† 
 Fever and arthralgia    
  None 1,212 111 (9.2) <0.01 
  Only fever 322 38 (11.8)  
  Only arthralgia 89 20 (22.5)  
  Both, not simultaneous 40 7 (17.5)  
  Both, simultaneous 96 32 (33.3)  
 Myalgia    
  Yes 222 42 (18.9) <0.01 
  No 1,548 167 (10.8)  
 Rash    
  Yes 216 50 (23.2) <0.01 
  No 1,554 158 (10.2)  
 Pruritus    
  Yes 206 46 (22.3) <0.01 
  No 1,563 163 (10.4)  
Presumptive clinical diagnosis 
 Chikungunya    
  Yes 48 24 (50.0) <0.01 
  No 1,724 185 (10.7)  
 Dengue    
  Yes 111 21 (18.9) 0.02 
  No 1,661 188 (11.3)  
 Zika    
  Yes 147 38 (25.9) <0.01 
  No 1,625 171 (10.5)  
*Data not shown for 3 participants. 
†Reported symptoms with onset after January 2015. 
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with arthralgia (PR 2.26, 95% CI 1.43–3.57) after Janu-
ary 2015, but not for separate episodes of fever or ar-
thralgia (Table 2). 
Frequency of Symptomatic Infections among  
Participants with CHIKV IgG
Of the 209 participants with detected CHIKV IgG, 32 
(15.3%) recalled an episode of fever and arthralgia 
after January 2015. The median duration of arthral-
gia for these 32 positive participants was 5 (IQR 3–9) 
days; the longest duration was 60 days for 1 person. 
Participants with symptomatic infection tended to be 
older (p = 0.07); more frequently reported other clini-
cal manifestations compatible with CHIKV infection, 
such as myalgia, rash, and pruritus (p<0.01 for each 
symptom); and more commonly received a presump-
tive clinical diagnosis of chikungunya or Zika (p<0.01 
for both) but not of dengue (p = 0.62) (Table 3).
Frequency of Presumptive Clinical Diagnosis  
of Chikungunya
Among the 209 participants with a previous CHIKV 
infection, 24 (11.5%) reported receiving a clinical pre-
sumptive diagnosis of chikungunya. Although low, 
this frequency was 7.5 (95% CI 4.3–12.9) times greater 
than the 1.5% (24/1,563) frequency among the par-
ticipants who were negative for CHIKV IgG (p<0.01). 
Noteworthy for the 32 CHIKV-infected participants 
who had symptomatic disease, 20 (62.5%) reported a 
presumptive clinical diagnosis of chikungunya (Table 
3). On the other hand, of the 48 participants who re-
ported having received a clinical presumptive diag-
nosis of chikungunya, 24 had CHIKV IgG detected, 
indicating a positive predictive value of 50% for the 
presumptive diagnosis.
Frequency of CHIKV IgM 
Among the 209 participants who were positive for 
CHIKV IgG, 49 (23.4%) also had CHIKV IgM, possibly 
indicating a recent infection. We found no associations 
between sociodemographic or clinical characteristics 
and the presence of CHIKV IgM (data not shown).
Discussion
Despite retrospective evidence of a chikungunya 
outbreak in Salvador during June–November 2015 
(12,15), we found that ≈2 years later (November 
2016–February 2017), <12% of the subjects enrolled 
in this large cross-sectional neighborhood survey had 
been infected by CHIKV. This seroprevalence is much 
lower than that found in 3 additional CHIKV sero-
logic surveys performed in Brazil at that time. During 
November–December 2015, in Feira de Santana, ≈100 
km from Salvador, the prevalence of prior CHIKV 
infection was estimated at 57.1%; in the urban area 
of Riachão do Jacuípe, 185 km from Salvador, preva-
lence was estimated at 45.7% (29). In the rural area of 
Riachão do Jacuípe, the prevalence of prior CHIKV 
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Table 2. Crude and adjusted prevalence ratios for persons with previous chikungunya virus infection, by demographic and clinical 
characteristics, Salvador, Brazil, November 2016–February 2017 
Characteristic Crude prevalence ratio (95% CI)* Adjusted prevalence ratio (95% CI)† 
Sociodemographic  Model 1 
 Illiteracy 1.60 (0.99–2.60) 
 
 Not working 1.28 (0.97–1.68) 
 
 Residence located in an unpaved street 1.52 (1.07–2.15) 1.52 (1.07–2.15) 
 Type of residence construction   
  Plastered wall Referent 
 
  Unplastered wall 1.47 (0.92–2.35) 
 
  Wood/Other material 1.86 (1.06–3.28) 
 
Clinical: reported symptoms‡  Model 2 
 Fever and arthralgia  
 
  None Referent Referent 
  Only fever 1.29 (0.89–1.86) 0.96 (0.62–1.49) 
  Only arthralgia 2.45 (1.60–3.75) 1.55 (0.95–2.53) 
  Both, not simultaneous 1.91 (0.97–3.77) 1.22 (0.56–2.67) 
  Both, simultaneous 3.64 (2.51–5.28) 2.26 (1.43–3.57) 
 Myalgia 1.75 (1.23–2.50) 
 
 Rash 2.28 (1.68–3.08) 
 
 Pruritus 2.14 (1.51–3.03) 
 
 Presumptive clinical diagnosis   
  Chikungunya 4.66 (3.35–6.48) 2.83 (1.97–4.05) 
  Dengue 1.67 (1.09–2.56) 
 
  Zika 2.45 (1.78–3.39) 
 
*Crude prevalence ratios shown for variables with bivariate p values <0.20, selected for inclusion in the initial multiple variable model. 
†Two different multiple variable models were applied using backward selection. The first model included only sociodemographic variables to investigate 
potential exposures associated with CHIKV infection; the second model included only clinical characteristics to investigate predictors of seropositivity.  
‡Reported symptoms with onset after January 2015. 
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infection was 20.0% in April 2016 (30). It is unlikely 
that a gradual decrease in the IgG levels over time in-
fluenced these differences, because we surveyed the 
participants relatively soon after the outbreak. Thus, 
the wide range of prevalence levels in adjacent cities 
most possibly indicates that the intensity of CHIKV 
transmission, after its first introduction, may vary 
greatly even among relatively close locations. 
Serum surveys performed in Haiti during De-
cember 2014 and February 2015, about 1 year af-
ter detection of the index case in the country, also 
found large variations in the seroprevalence (mean 
of 78.4% for the urban sites and 44.9% for the rural 
sites) (31). These differences may be related to Ae-
des spp. infestation levels and diversity, variations 
in local geographic and climate conditions, the pre-
dominant CHIKV strain circulating, and even by in-
teractions when the vector species may be coinfected 
with CHIKV and other circulating arboviruses, such 
as ZIKV and DENV. Furthermore, a very localized 
and self-restricted CHIKV outbreak has been recent-
ly described in Salvador (32), which suggests that lo-
cal environmental characteristics and patterns of hu-
man activity and movement in specific regions may 
be responsible for the emergence of CHIKV and the 
extent of its spread. 
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Table 3. Comparison of sociodemographic and clinical characteristic of participants with symptomatic versus asymptomatic 
chikungunya virus infection Salvador, Brazil, November 2016 to February 2017* 
Characteristic 
Disease status of infected participants, no. %† 
p value Symptomatic, n = 32 Asymptomatic, n = 177 
Sociodemographic 
 Sex    
  M 12 (37.5) 81 (45.8) 0.39 
  F 20 (62.5) 96 (54.2)  
 Age, y    
  5–14 2 (6.3) 40 (22.6) 0.07 
     15–39 22 (68.8) 82 (46.3)  
  ≥40 8 (24.9) 55 (31.1)  
 Education‡    
  Illiterate 1 (3.1) 13 (7.4) 0.42 
  Literate 31 (96.9) 163 (92.6)  
 Skin color    
  White 0 10 (5.7) NA 
  Nonwhite 32 (100) 167 (94.3)  
 Household per capita income, US$/day‡    
  ≤5.50 27 (84.4) 144 (81.8) 0.73 
  >5.50 5 (15.6) 32 (18.2)  
Clinical: reported symptoms 
 Fever and arthralgia    
  None 0 111 (62.7) <0.01 
  Only fever 0 39 (22.0)  
  Only arthralgia 0 20 (11.3)  
  Both, not simultaneous 0 7 (4.0)  
  Both, simultaneous 32 (100) 0  
 Myalgia    
  Yes 18 (56.3) 24 (13.6) <0.01 
  No 14 (43.7) 153 (86.4)  
 Rash    
  Yes 22 (68.7) 28 (15.9) <0.01 
  No 10 (31.3) 148 (84.1)  
 Pruritus    
  Yes 21 (65.6) 25 (14.1) <0.01 
  No 11 (34.4) 152 (85.9)  
Presumptive clinical diagnosis 
 Chikungunya    
  Yes 20 (62.5) 12 (6.8) <0.01 
  No 12 (37.5) 165 (93.2)  
 Dengue    
  Yes 4 (12.5) 17 (9.6) 0.62 
  No 28 (87.5) 160 (90.4)  
 Zika    
  Yes 18 (56.3) 20 (11.3) <0.01 
  No 14 (43.7) 157 (88.7%)  
*NA, not available 
†CHIKV disease status was defined as symptomatic on the basis of self-reported fever accompanied by arthralgia after January 2015. 
‡Data not available for 1 participant with an asymptomatic CHIKV infection. 
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In bivariate analyses, we found that structural 
deficiencies in the housing and on the streets where 
the houses were located were associated with previ-
ous CHIKV infection, pointing to a social gradient 
that poses an increased risk for virus exposure among 
the most vulnerable residents. Urban areas served by 
unpaved streets and where the walls of houses are 
not plastered, or made of wood or of other mate-
rial other than brick, often also lack basic sanitation 
services, such as regular garbage collection and po-
table water. These conditions, in turn, influence im-
proper disposal of trash and accumulation of water 
in containers, both well-known breeding grounds for 
Aedes mosquitoes. 
In addition, low education levels in such settings 
may limit residents’ ability to access, understand, 
and act on information about measures to prevent 
mosquitoborne diseases (33,34). Individual- and 
ecologic-level studies in rural Kenya (35), Nicaragua 
(36), and Colombia (37) have also showed that socio-
economic vulnerability and living near sites where 
water accumulates are associated with increased 
chikungunya incidence. 
The widely accepted understanding of CHIKV 
infection has been that the majority (>70%) of infected 
persons develop a symptomatic form of the disease 
(1). We, conversely, found a frequency of symptom-
atic infection, defined by having arthralgia accompa-
nied by fever, of only 15.3%. Other studies have also 
found low proportions of symptomatic CHIKV infec-
tion. In Brazil, serologic surveys estimated the pro-
portion of symptomatic CHIKV infection to be 32.7% 
in Feira de Santana and 41.2% in Riachão do Jacuípe 
(29). Prospective cohort studies, a more robust study 
design for determining the natural history of disease, 
have also found low proportions of symptomatic in-
fections. For example, during a cohort follow-up in 
the Philippines, the subclinical incidence of CHIKV 
infection was 10.0 per 100 person-years, while the in-
cidence of symptomatic CHIKV infection was 2.2 per 
100 person-years, indicating that <20% of those in-
fected exhibited symptoms (38). However, because of 
the small geographic range of the studies, these find-
ings should be considered limited. 
Differences in symptomatic infection rates may 
be related to the lineage of CHIKV that is circulat-
ing (39,40), the diversity in human immunological 
responses driven by specific genetic characteristics 
(41), or even by the CHIKV exposure dose delivered 
by mosquitoes (42). In our study, we found that both 
women and persons ≥15 years of age were more like-
ly to have symptomatic CHIKV infections than oth-
ers, but the power of our analyses was limited by the 
small number of CHIKV infections that we detected. 
However, our results are in accordance with other 
studies that suggest that women are at increased risk 
for symptomatic disease and that risk for symptomat-
ic disease increases with age (29). Further cohort stud-
ies are needed to determine the factors that may in-
fluence whether the infection becomes symptomatic. 
We also found that chronic arthralgia after CHIKV in-
fection was uncommon; the maximum reported dura-
tion for the articular pain was 60 days, observed in 
just 1 (0.5%) of the 209 CHIKV-infected persons. 
On the basis of these findings, we hypothesize 
that asymptomatic and milder clinical manifesta-
tions with less severe arthralgia and low rates of the 
disease becoming chronic may occur under certain 
circumstances of CHIKV infection. If further inves-
tigation supports this hypothesis, this finding might 
partially explain the low proportion of participants 
testing positive for CHIKV who received a correct 
presumptive diagnosis. 
We did find that report of a presumptive clinical 
diagnosis of chikungunya disease was strongly associ-
ated with having CHIKV IgG (positive predictive val-
ue of 50%). Thus, during and after outbreaks, persons 
exhibiting CHIKV-associated symptoms and suspect-
ed disease should be clinically tested because of the 
likelihood of having confirmed chikungunya disease. 
Our study findings have limitations. First, we 
surveyed just 1 neighborhood of Salvador and, thus, 
could not capture potential variations in prior expo-
sure to CHIKV within the city. However, because the 
community where we conducted the study has poor 
sanitation infrastructure, which is associated with a 
higher density of Aedes aegypti mosquitoes, and high 
population density, associated with greater risk of 
arboviral transmission, it is unlikely that the CHIKV 
seroprevalence of the city population overall was 
much higher than the one we measured in the Pau da 
Lima community. 
Second, we used a commercial CHIKV IgG ELI-
SA to detect previous CHIKV infections. Prior studies 
have reported high accuracy levels for this test (sen-
sitivity 88%–100%, specificity 82%–95% (43,44). In 
our ELISA retesting of 100 IgG negative samples, we 
found that cryoglobulinemia likely did not influence 
our seroprevalence; moreover, we found an excellent 
agreement between the IgG ELISA and the PRNT90. 
However, because cryoglobulinemia had been de-
scribed for CHIKV (45), further surveys should con-
sider this possible effect. 
Third, although transmission of other alphavi-
ruses, such as Mayaro and o’nyong-nyong, has not 
been reported in northeastern Brazil, because we 
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did not perform PRNT90 for other alphaviruses, we 
cannot completely rule out the possibility of cross-
reactions. In addition, it has been shown that IgG 
seroconversion might not occur or may occur at 
later stages after CHIKV infection, possibly due to 
a strong and longlasting CHIKV IgM immune re-
sponse (46). It is possible that this diagnostic limi-
tation hampered detection of some cases of CHIKV 
infection, especially those occurring shortly before 
the survey was conducted. 
Fourth, the proportion of symptomatic infections 
may have been underestimated because of the 2-year 
gap between the chikungunya outbreak in Salvador 
and when the study was conducted and because we 
did not consider those reporting only fever or only 
arthralgia to have symptomatic disease. Thus, the ob-
served symptomatic rate from our study should be 
considered a minimum level. Last, the cross-sectional 
design made it difficult to determine the temporal 
relation between exposures to risk and occurrence of 
CHIKV infection. 
In summary, our findings suggest that although 
CHIKV and ZIKV both spread through Salvador 
in the same year, 2015 (12,15,47), transmission of 
CHIKV seems to have been much less intense, reach-
ing ≈12% of the population, compared to estimates of 
63%–73% for ZIKV (22,48). Viral competition within 
hosts and vectors may be a key element in explaining 
this dynamic. Further comparative studies on immu-
nopathogenesis and vectorial competence are needed 
to clarify why these 2 arboviruses, transmitted by the 
same mosquito vectors, presented such different pat-
terns of transmission spread, given that the popula-
tion was completely naive for both of them. 
Our findings also show that other parts of Bra-
zil and the Americas may be largely susceptible to 
CHIKV transmission. It is thus necessary to maintain 
surveillance to promptly detect further epidemics 
and to invest in developing and evaluating target in-
terventions, such as vaccines and novel approaches 
for vector control, that will help protect the popula-
tion from CHIKV and other arboviral infections. 
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